A new Beginning..., page-2329

The app has not failed in the US a submission is about to be lodged.
The first round issues where mostly dealt with and the reasons for 3 diseases below a pass in the US are below ( although waiting on croup so could be 2)

The app was a success in 6 diseases in AU it is the same app used in America,
There is a different set of standards/ practices in place. In the US


“Comparing these results to our Australian Breathe Easy study, we see the result of differing clinical practices between Australia and the United States, driven by a substantially different healthcare and insurance system. We also see a large number of patients (33%) requiring a third adjudicator, illustrating the difficulty in making a clinical diagnosis even with access to all the tests available in a modern tertiary hospital.”

The algorithms agreed with the final consensus more often than either of the first two adjudicators, which is excellent.

“It is clear that in the US pneumonia diagnosis is materially different to what we saw in our Australian study. We see a significantly higher incidence of chest x-ray usage and higher dependence on those chest x-rays, despite their fallibility. Also, if the adjudicators, who are the reference, only agree 66% of the time then clearly, pneumonia diagnosis in the US is not as rigid and repeatable as it may be elsewhere. In such circumstances, it’s statistically difficult for ResAppDx to achieve performance figures that are much different than the figures achieved by the adjudicators themselves.”

The substantial degree of disparity between clinicians’ diagnosis further highlights the need and value of an objective diagnostic tool.




Not investment advice, do your own research, and consult a licensed adviser